You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – The US Food and Drug Administration on Friday approved lisocabtagene maraleucel (Bristol Myers Squibb's Breyanzi) as a treatment for relapsed or refractory large B-cell lymphoma.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.